Published in Leukemia on March 01, 2002
European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci (2014) 1.08
Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy. Int J Hematol (2008) 1.00
Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan. Int J Clin Oncol (2011) 0.78
Application of a Euryarchaeota-Specific Helicase from Thermococcus kodakarensis for Noise Reduction in PCR. Appl Environ Microbiol (2016) 0.75
Changing treatment may affect the predictive ability of European Treatment Outcome Study scoring on the prognosis of patients with chronic myeloid leukemia. Turk J Haematol (2016) 0.75
A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med (1993) 6.18
Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med (1994) 5.28
Characterization of a candidate bcl-1 gene. Mol Cell Biol (1991) 2.48
Invasive Haemophilus influenzae disease in adults. A prospective, population-based surveillance. CDC Meningitis Surveillance Group. Ann Intern Med (1992) 2.33
Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol (2000) 2.29
Amplification of mitochondrial DNA in acute myeloid leukaemia. Br J Haematol (1996) 2.17
Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet (1996) 2.06
Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2001) 2.00
A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood (1999) 1.97
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 1.93
Phytohaemagglutinin activation of T cells through the sheep red blood cell receptor. Nature (1985) 1.89
Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. Br J Haematol (1997) 1.83
Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet (2003) 1.80
A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene (2006) 1.73
Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet (1990) 1.71
A common mechanism of chromosomal translocation in T- and B-cell neoplasia. Science (1986) 1.62
PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia (2005) 1.61
The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood (1993) 1.55
Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med (1984) 1.54
TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia (2008) 1.50
Human macrophage colony-stimulating factor levels are elevated in pregnancy and in immune thrombocytopenia. Blood (1992) 1.49
Fc gamma RII, but not erythropoietin or GM-CSF, mediates calcium mobilization in fetal hemopoietic blast cells. Exp Hematol (1992) 1.45
Cushing's syndrome--killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet (1982) 1.45
Lack of effect of granulocyte-macrophage and granulocyte colony-stimulating factors on cultured human endothelial cells. Blood (1991) 1.43
Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol (1987) 1.42
Investigation of early T cell activation: analysis of the effect of specific antigen, interleukin 2 and monoclonal antibodies on intracellular free calcium concentration. Eur J Immunol (1985) 1.41
X-chromosome inactivation patterns using HPRT and PGK polymorphisms in haematologically normal and post-chemotherapy females. Br J Haematol (1991) 1.39
Acute-phase response in patients given rhIL-3 after chemotherapy. Lancet (1992) 1.39
Tissue specificity of X-chromosome inactivation patterns. Blood (1994) 1.37
Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann Intern Med (1995) 1.37
Human embryonic haemoglobins Gower 1 and Gower 2. Nature (1979) 1.30
CD2 and CD3 antigens mobilize Ca2+ independently. Eur J Immunol (1986) 1.29
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia (2009) 1.29
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol (1995) 1.29
Phenotypic analysis of fetal blood leucocytes: potential for prenatal diagnosis of immunodeficiency disorders. Prenat Diagn (1982) 1.28
Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol (1994) 1.28
Signal transduction in human T lymphocytes. Immunol Rev (1987) 1.21
Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood (1989) 1.17
Different pathways of human T-cell activation revealed by PHA-P and PHA-M. Immunology (1986) 1.16
Increased risk of meningitis and bacteremia due to Listeria monocytogenes in patients with human immunodeficiency virus infection. Clin Infect Dis (1993) 1.15
T cell receptor gene rearrangements define a monoclonal T cell proliferation in patients with T cell lymphocytosis and cytopenia. Blood (1986) 1.15
High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia. Leukemia (2006) 1.14
Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant (2008) 1.14
Dynamics of telomere shortening in neutrophils and T lymphocytes during ageing and the relationship to skewed X chromosome inactivation patterns. Br J Haematol (2000) 1.14
Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol (2001) 1.12
Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. MRC Adult Leukaemia Working Party. Br J Haematol (1997) 1.10
Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood (1996) 1.08
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant (2008) 1.08
Streptococcus suis serotypes associated with disease in weaned pigs. Aust Vet J (1990) 1.08
A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft. Leuk Lymphoma (2007) 1.08
Growth factor withdrawal from primary human erythroid progenitors induces apoptosis through a pathway involving glycogen synthase kinase-3 and Bax. Blood (2001) 1.07
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia (2013) 1.07
Activation of human monocytes occurs on cross-linking monocytic antigens to an Fc receptor. J Immunol (1989) 1.06
Advancing the spontaneous hypertensive rat model of attention deficit/hyperactivity disorder. Behav Neurosci (2008) 1.06
T cell disorders in haematological diseases. Clin Haematol (1982) 1.05
Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood (2001) 1.03
Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation (1989) 1.03
Prenatal diagnosis of three cases of severe combined immunodeficiency: severe T cell deficiency during the first half of gestation in fetuses with adenosine deaminase deficiency. Clin Exp Immunol (1984) 1.03
Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer (1994) 1.02
Transient leucopenia induced by granulocyte-macrophage colony-stimulating factor. Lancet (1987) 1.02
PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. Leukemia (2012) 1.01
Characterization of cell cycle status and E2F complexes in mobilized CD34+ cells before and after cytokine stimulation. Blood (1997) 1.01
The effect of mitogenic lectins and monoclonal antibodies on intracellular free calcium concentration in human T-lymphocytes. Biochem J (1984) 1.01
T cell regeneration after allogeneic and autologous bone marrow transplantation. Br J Haematol (1983) 0.99
Histopathological changes in simian immunodeficiency virus infection. J Pathol (1990) 0.99
Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes. Bone Marrow Transplant (2004) 0.98
Mechanism of human monocyte activation via the 40-kDa Fc receptor for IgG. J Immunol (1988) 0.98
The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol (1997) 0.98
Differential effects of granulocyte- and granulocyte-macrophage colony-stimulating factors (G- and GM-CSF) on neutrophil adhesion in vitro and in vivo. Eur J Haematol (1992) 0.98
A sensitive mutation-specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: the first report of a codon 227 mutation in bone. Histopathology (2007) 0.97
Development and evaluation of an internally controlled semiautomated PCR assay for quantification of cell-free cytomegalovirus. J Med Virol (2002) 0.97
The phosphorylation state of the retinoblastoma (RB) protein in G0/G1 is dependent on growth status. Oncogene (1991) 0.97
Selective peripheral blood eosinophilia associated with survival advantage in Hodgkin's disease (BNLI Report No 31). British National Lymphoma Investigation. J Clin Pathol (1987) 0.96
An erythrocyte membrane-protein anomaly in march haemoglobinuria. Lancet (1979) 0.94
Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet (1994) 0.94
Transmigration of CD34+ cells across specialized and nonspecialized endothelium requires prior activation by growth factors and is mediated by PECAM-1 (CD31). Blood (1998) 0.94
Frequency of CBF beta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. The MRC Adult Leukaemia Working Party. Br J Haematol (1997) 0.94
The relationship between mitogen-induced membrane potential changes and intracellular free calcium in human T-lymphocytes. Biochim Biophys Acta (1986) 0.94
Prenatal diagnosis of immunodeficiency disorders. Br Med Bull (1983) 0.94
Granulocyte-macrophage colony-stimulating factor induces neutrophil adhesion to pulmonary vascular endothelium in vivo: role of beta 2 integrins. Blood (1992) 0.93